Translate Bio — Investor Presentation (January 2020)
25 slides from Translate Bio's investor presentation, Jan 13, 2020
Slide 1: Transforming mRNA science into healthy expression
Transforming mRNA science into healthy expression Corporate Presentation January 2020 Exhibit 99.1
Slide 2: Cautionary Note Regarding Forward-Looking Statements and Legal Disclaimers
Cautionary Note Regarding Forward-Looking Statements and Legal Disclaimers This presentation contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and
Slide 3: Highly-Differentiated mRNA Therapeutics Company
1st mRNA therapy in clinic for chronic disease Early encouraging clinical activity with ppFEV1 improvement Building off capabilities established for CF program 3 additional programs: primary ciliary dyskinesia idiopathic pulmonary fibrosis pulmonary arterial hypertension Preclinical data in multiple
Slide 4: Leveraging RNA and Delivery Expertise to Treat Pulmonary Diseases
Treating a monogenic disease with mRNA to replace a defective or missing protein MRT5005 Discovery program for additional CFTR protein/lipid approach Leveraging RNA and Delivery Expertise to Treat Pulmonary Diseases Treating a disease with mRNA and/or siRNA to address complex disease with multifacet
Slide 5: Unlocking the Power of RNA and Delivery to Expand Our Toolkit
Unlocking the Power of RNA and Delivery to Expand Our Toolkit Delivery mRNA siRNA mRNA Engineered Proteins Delivery siRNA Foundational Technology Technology Expansion Wild Type Protein Wild Type Protein Protein Degradation
Slide 6: Translate Bio's Broadly Applicable Platform Fuels Our Pipeline
Translate Bio’s Broadly Applicable Platform Fuels Our Pipeline Focus Area Indication Route of Administration Discovery IND-Enabling Phase 1 / 2 Clinical Direct Therapeutics LUNG Cystic Fibrosis (CF) Inhalation Cystic Fibrosis (CF) Inhalation Idiopathic Pulmonary Fibrosis (IPF) Inhalation Primary Cil
Slide 7: Pulmonary Delivery of CFTR mRNA: Cystic Fibrosis MRT Program
Pulmonary Delivery of CFTR mRNA Cystic Fibrosis MRT Program
Slide 8: MRT5005: Designed to Address the Underlying Cause of CF Regardless of Mutation
Weekly self-administered nebulization Significant improvements in lung function Halt the progressive decline in lung function Substantially reduce the frequency of pulmonary exacerbations Deliver mRNA encoding fully functional CFTR protein to the lung Initial development focused on patients non-amen
Slide 9: Significant Number of Patients Lack Treatment Despite Trikafta Approval
13.6% 9.4% Genotyped Patients Eligible for Trikafta™ 66,580 patients ~$9.0B1 (2030) Genotyped Patients Eligible for Kalydeco® 11,750 patients $1.0B (actual sales in 2018) Genotyped Patients Not Amenable to Modulators 8,100 patients 77.0% Cystic Fibrosis Patients WW 86,430 patients in U.S., EU, Canad
Slide 10: Significant Number of Patients Lack Treatment Despite Trikafta Approval
13.6% 9.4% Genotyped Patients Eligible for Trikafta™ 66,580 patients ~$9.0B1 (2030) Genotyped Patients Eligible for but Potentially Not Taking Trikafta™ 2 Cannot tolerate, contraindicated No FEV1 response Low (0-5%) FEV1 response 57.2% Cystic Fibrosis Patients WW 86,430 patients in U.S., EU, Canada,
Slide 11: Phase 1/2 Clinical Trial Design
PART A: Single Ascending Dose (SAD) Groups 8 mg 16 mg 24 mg 12 Patients Total Phase 1/2 Clinical Trial Design Design Randomized, double-blind, placebo-controlled, staggered dosing Each cohort: N=4 (3:1) Objective Evaluate safety and tolerability of single and multiple escalating doses of MRT5005 adm
Slide 12: Positive Interim Results: First-in-Human Phase 1/2 Clinical Trial of MRT5005 in Patients with CF
Positive Interim Results: First-in-Human Phase 1/2 Clinical Trial of MRT5005 in Patients with CF First mRNA therapeutic administered for a chronic disease and first to be administered via inhalation Generally well-tolerated at low- and mid-dose levels; No serious adverse events reported at any dose
Slide 13: Marked Increases in ppFEV1 Observed After Single Dose of MRT5005, Primarily at Mid-Dose
Marked Increases in ppFEV1 Observed After Single Dose of MRT5005, Primarily at Mid-Dose Mean Absolute Change from Baseline in ppFEV1 Patients in the 16 mg dose demonstrated: Mean maximum increase from baseline of 15.7% Individual maximal ppFEV1 increases of 11.1%, 13.6% and 22.2% 2 of the 3 had a st
Slide 14: Rapid FEV1 Increases Correlate with Time Course of CFTR Protein Expression
Rapid FEV1 Increases Correlate with Time Course of CFTR Protein Expression Biosynthesis & Maturation of CFTR (Riordan JR 2008) 0 minutes CFTR mRNA transcription (t½=13-24 hours) 5-10 minutes Translation and core glycosylation, complete 30 minutes Final high molecular weight glycosylation 2 hours Cel
Slide 15: How Much CFTR Do You Need to be Effective?
How Much CFTR Do You Need to be Effective? CFTR delivery to 25% of the lung surface epithelial cells restores normal mucus transport rates in vitro Zhang L et al. PLoS Biol 2009 No Symptoms 100% 50% CFTR Function % Obligate Heterozygotes CF-related Disease 0% Cystic Fibrosis Healthy Subjects CFTR ex
Slide 16: Approved CFTR Modulators Have Shown ppFEV1 Increases from 2-14%
Approved CFTR Modulators Have Shown ppFEV1 Increases from 2-14% * Patients received Symdeko® during a 4-week run-in period and were then randomized to receive Trikafta™ or Symdeko® during a 4-week double-blind treatment period.
Slide 17: Safety: MRT5005 Generally Well-Tolerated at Low- and Mid-Dose Levels
Safety: MRT5005 Generally Well-Tolerated at Low- and Mid-Dose Levels No SAEs at any dose Most common AEs – cough, headache Generally well-tolerated at low- and mid-dose levels Primarily at high dose, patients experienced transient, mild-moderate febrile reactions Occurred ~4-10 hours post dosing Sym
Slide 18: Updated Phase 1/2 Clinical Trial Protocol: Two Additional Dose Cohorts
Updated Phase 1/2 Clinical Trial Protocol: Findings Support Exploration of Two Additional Dose Cohorts Up to 16 Patients 8 Patients Total Select dose level Select dose level PART B EXPANSION: Multiple Ascending Dose (MAD) Groups 5 weekly doses PART A: Single Ascending Dose (SAD) Groups 8 mg 16 mg 24
Slide 19: Interim Data from Phase 1/2: First mRNA Therapeutic for Cystic Fibrosis
Interim Data from Phase 1/2: First mRNA Therapeutic for Cystic Fibrosis ppFEV1 Safety Marked increases in ppFEV1 within the 8 days after treatment in 4 patients, including all 3 patients in 16 mg dose group Early improvement in ppFEV1 suggests MRT5005 crossing the mucus layer enabling production of
Slide 20: Discovery Efforts Driving Future Pipeline Programs
Discovery Efforts Driving Future Pipeline Programs
Slide 21: Focused Innovation with Pulmonary Delivery
Focused Innovation with Pulmonary Delivery Inhalation may provide local efficacy while minimizing systemic toxicity 83,000 diagnosed cases of IPF in the U.S.2 Opportunity to address a range of protein targets to potentially reverse the disease 53,000 diagnosed cases of PAH in the U.S.2 Idiopathic Pu
Slide 22: Progress in Sanofi Pasteur Vaccine Collaboration
Progress in Sanofi Pasteur Vaccine Collaboration mRNA Production LNP Production Multiple Disease Programs Screened several infectious disease targets Multiple grams of mRNA produced for preclinical studies Large scale process development complete for lead mRNA constructs Over a dozen different struc
Slide 23: Robust Approach to Generating and Validating Next-generation Delivery Technologies
Robust Approach to Generating and Validating Next-generation Delivery Technologies High-throughput parallel synthesis for efficient library production with different structural cores and testing in vivo Prototype established for high-throughput LNP production Dan Anderson (MIT): Collaboration dating
Slide 24: Anticipated Milestones Over Next 18 Months
MRT5005 (CF) Report data from MAD portion of Phase 1/2 clinical trial and additional 20 mg SAD dose group 3Q 2020 Anticipated Milestones Over Next 18 Months Pipeline Programs Sanofi Pasteur collaboration: advance lead candidate towards IND CF discovery: preclinical safety, protein expression, durati
Slide 25: Thank you
Thank you